Primary Progressive Aphasia With Suspected Alzheimer's Disease
Conditions
Brief summary
The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.
Interventions
DEVICEPET
PET scanner for brain imaging
DRUG18F-AV-1451
Sponsors
National Institute on Aging (NIA)
University of Chicago
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Must have primary progressive aphasia
Exclusion criteria
* Pregnancy * Breastfeeding * Receiving radiation clinically
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tau levels in PPA participants | 2 years | Tau deposition as measured by 18F-AV-1451 standardized uptake value ratio (SUVR) in cortical and medial temporal regions. |
Countries
United States
Outcome results
None listed